Literature DB >> 1520842

From experimental units to unique experiments: chronobiologic pilots complement large trials.

F Halberg1, G Cornélissen, C Bingham, S Fujii, E Halberg.   

Abstract

The timing of treatment affects outcome. For mapping multi-frequency rhythm spectra first to optimize chronochemotherapy, 1000 marker determinations on the subject are more informative than a few determinations on each of hundreds of patients. N-of-6 subgroups should follow, with one subject assigned to each of 6 marker rhythm stages, 60 (e.g. 4 hours on a 24-hour scale) apart. Once the time structure has been mapped, minimal sampling requirements determined, and guidelines for treatment established, the information gained from chronobiologic n-of-1 and n-of-6 test pilot designs can be built cost-effectively into randomized controlled trials to benefit large patient populations. Sequential tests combined with marker rhythmometry and cosinor analysis on single test subjects, small groups and eventually on each patient are powerful tools that can extract information otherwise unattainable even at great cost and bring the P-value from publications to the patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1520842

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  3 in total

Review 1.  Cancer chronomics III. Chronomics for cancer, aging, melatonin and experimental therapeutics researchers.

Authors:  Franz Halberg; Germaine Cornélissen; Waldemar Ulmer; Mikhail Blank; William Hrushesky; Patricia Wood; Rajesh K Singh; Zhengrong Wang
Journal:  J Exp Ther Oncol       Date:  2006

Review 2.  Cancer chronomics II. Origins of timing cancer treatment.

Authors:  Germaine Cornélissen; Mikhail Victorovich Berezkin; Elena V Syutkina; Mikhail A Blank; Olga A Blank; Sergei M Chibisov; Franz Halberg
Journal:  J Exp Ther Oncol       Date:  2006

3.  Cancer chronomics I. Origins of timed cancer treatment: early marker rhythm-guided individualized chronochemotherapy.

Authors:  Franz Halberg; Konald Prem; Francine Halberg; Catherine Norman; Germaine Cornélissen
Journal:  J Exp Ther Oncol       Date:  2006
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.